Your browser doesn't support javascript.
loading
Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia.
Berrazouane, Sofiane; Boisvert, Marc; Salti, Suzanne; Mourad, Walid; Al-Daccak, Reem; Barabé, Frédéric; Aoudjit, Fawzi.
Affiliation
  • Berrazouane S; Division of Immune and Infectious Diseases, CHU de Québec-Université Laval Research Center, Quebec city, Canada.
  • Boisvert M; Division of Immune and Infectious Diseases, CHU de Québec-Université Laval Research Center, Quebec city, Canada.
  • Salti S; CHUM Research Center and Faculty of Medicine, Université de Montréal, Montreal, Canada.
  • Mourad W; CHUM Research Center and Faculty of Medicine, Université de Montréal, Montreal, Canada.
  • Al-Daccak R; Hôpital St-Louis, INSERM Unit 976, Université Paris-Diderot, Paris, France.
  • Barabé F; Division of Immune and Infectious Diseases, CHU de Québec-Université Laval Research Center, Quebec city, Canada.
  • Aoudjit F; Department of Medicine, Faculty of Medicine, Université Laval, Quebec city, Canada.
Cell Death Dis ; 10(5): 357, 2019 05 01.
Article in En | MEDLINE | ID: mdl-31043590
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Doxorubicin / Gene Expression Regulation, Leukemic / Integrin beta1 / Focal Adhesion Kinase 2 / Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Antibiotics, Antineoplastic Type of study: Prognostic_studies Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Doxorubicin / Gene Expression Regulation, Leukemic / Integrin beta1 / Focal Adhesion Kinase 2 / Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Antibiotics, Antineoplastic Type of study: Prognostic_studies Language: En Year: 2019 Type: Article